These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 31207705)
41. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Kanamori H; Usuki K; Uoshima N; Yanada M; Takeuchi J; Mizuno I; Kanda J; Okamura H; Yano S; Tashiro H; Shindo T; Chiba S; Tomiyama J; Inokuchi K; Fukuda T Int J Hematol; 2020 Aug; 112(2):200-209. PubMed ID: 32495317 [TBL] [Abstract][Full Text] [Related]
42. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102 [TBL] [Abstract][Full Text] [Related]
43. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia]. Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604 [TBL] [Abstract][Full Text] [Related]
44. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617 [TBL] [Abstract][Full Text] [Related]
46. [Influence of FLT3-ITD Mutation and ITD Length on the Outcome on Patients with Acute Myeloid Leukemia]. Chen F; Jiang XJ; Yin CX; Zhong QX; Jiang L; Yu GP; Sun J; Meng FY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):678-683. PubMed ID: 29950203 [TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study. Miyashita N; Onozawa M; Yoshida S; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Fujisawa S; Mori A; Ota S; Kakinoki Y; Tsutsumi Y; Yamamoto S; Miyagishima T; Nagashima T; Ibata M; Wakasa K; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Kondo T; Teshima T Int J Hematol; 2023 Jul; 118(1):36-46. PubMed ID: 36853451 [TBL] [Abstract][Full Text] [Related]
48. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy]. Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890 [No Abstract] [Full Text] [Related]
49. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746 [TBL] [Abstract][Full Text] [Related]
50. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114 [TBL] [Abstract][Full Text] [Related]
52. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation]. Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642 [TBL] [Abstract][Full Text] [Related]
53. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202 [TBL] [Abstract][Full Text] [Related]
54. [Expression of Du D; Zhu L; Wang Y; Ye X Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 May; 48(1):50-57. PubMed ID: 31102358 [TBL] [Abstract][Full Text] [Related]
55. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276 [TBL] [Abstract][Full Text] [Related]
56. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia]. Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272 [TBL] [Abstract][Full Text] [Related]
57. Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia. Mahmood R; Altaf C; Malik HS; Khan SA Pak J Med Sci; 2019; 35(1):23-28. PubMed ID: 30881390 [TBL] [Abstract][Full Text] [Related]
58. Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status. Cesano A; Putta S; Rosen DB; Cohen AC; Gayko U; Mathi K; Woronicz J; Hawtin RE; Cripe L; Sun Z; Tallman MS; Paietta E PLoS One; 2013; 8(2):e56714. PubMed ID: 23431389 [TBL] [Abstract][Full Text] [Related]
59. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Tiribelli M; Geromin A; Michelutti A; Cavallin M; Pianta A; Fabbro D; Russo D; Damante G; Fanin R; Damiani D Cancer; 2011 May; 117(10):2156-62. PubMed ID: 21523728 [TBL] [Abstract][Full Text] [Related]
60. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan. Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q Gene; 2020 Feb; 726():144195. PubMed ID: 31669649 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]